16
Jan

Sarepta’s up-and-down quest to get eteplirsen in the hands of patients with Duchenne muscular dystrophy is looking a little sunnier thanks to more promising data and an optimistic reading of some FDA tea leaves, news that sent the biotech’s shares up 35% on Thursday.

…read more

Source: Sarepta jumps on fresh optimism for an early approval

    

0 No comments